---
title: "CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283702622.md"
description: "CStone Pharmaceuticals has successfully completed a share placement, raising over HK$1 billion by issuing 118 million shares at HK$8.97 each. This represents about 7.4% of the enlarged share capital and was priced at a 7.3% discount to the recent five-day average. The funds will enhance the company's capital base for ongoing operations and growth in the oncology sector. Previous placements in April and July 2025 raised approximately HK$232.29 million and HK$467.28 million, respectively. CStone focuses on developing innovative oncology therapies and is listed on the Hong Kong Stock Exchange."
datetime: "2026-04-22T14:07:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283702622.md)
  - [en](https://longbridge.com/en/news/283702622.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283702622.md)
---

# CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

CStone Pharmaceuticals ( (HK:2616) ) has shared an announcement.

CStone Pharmaceuticals has completed a new share placement under its general mandate, issuing 118 million shares at HK$8.97 each to at least six institutional and professional investors, raising net proceeds of about HK$1.05 billion. The new shares represent roughly 7.4% of the enlarged share capital and were priced at a 7.3% discount to the recent five-day average, extending a series of equity financings that have strengthened the company’s capital base for ongoing operations and growth plans.

The company detailed that earlier placements in April and July 2025 raised net proceeds of approximately HK$232.29 million and HK$467.28 million, respectively, with the April funds now fully used and about HK$432.45 million from the July placement still unspent as of March 31, 2026. The latest transaction underscores continued investor appetite for the stock and provides additional financial flexibility to fund its development and commercialization strategy in the competitive oncology pharmaceutical sector.

**More about CStone Pharmaceuticals**

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative oncology therapies. Listed on the Hong Kong Stock Exchange, the company targets both domestic and international markets with a pipeline and portfolio centered on cancer treatments and related pharmaceutical products.

**Average Trading Volume:** 14,427,590

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$14.8B

For an in-depth examination of 2616 stock, go to TipRanks’ Overview page.

### Related Stocks

- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)

## Related News & Research

- [CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone](https://longbridge.com/en/news/286244356.md)
- [CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007](https://longbridge.com/en/news/283271354.md)
- [Sensorion Appoints Fred Chereau as Chief Executive Officer](https://longbridge.com/en/news/286719182.md)
- [Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026](https://longbridge.com/en/news/286795160.md)
- [09:03 ETOrthoArizona Expands Pinnacle Pain with New Chandler Facility and New Physician](https://longbridge.com/en/news/287070954.md)